**Original Research Article**

**Antibiotic susceptibility profile and extended spectrum β-lactamases production by uropathogenic *Escherichia coli* from tertiary care hospital of rural settings**

Mustafa Sofiur Rahman¹, Ritu Garg²*, Varsha A. Singh², Dipankar Biswas³

¹Tutor, Shri Shankaracharya Institute of Medical Sciences, Bhilai, Chhattisgarh, India
²Department of Microbiology, Markandeshwar University of Health Sciences & Research, Mullana, Haryana, India
³Junior Resident, Maharishi Markandeshwar Institute of Sciences & Research, Mullana, Haryana, India

Received: 07 October 2018
Accepted: 29 October 2018

*Correspondence:
Dr. Ritu Garg,
E-mail: dr_rittu07@yahoo.co.in

Copyright: © the author(s), publisher and licensee Medip Academy. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

---

**ABSTRACT**

**Background:** *Escherichia coli* are the most common cause of urinary tract infections in community as well as hospital settings. Emergence of drug resistance in *Escherichia coli* due to various mechanisms makes the treatment options very limited. This study was undertaken to detect ESBLs in uropathogenic *Escherichia coli* isolates and to determine their antimicrobial susceptibility pattern in rural setting.

**Methods:** A prospective study was done on 502 *E. coli* isolates from clinically suspected cases of urinary tract infections (UTI) patients of all age groups. All samples were inoculated on Cysteine Lactose Electrolyte Deficient Agar (CLED). Organisms grown in pure culture were identified by standard biochemical tests. Antibiotic susceptibility test was done by the Kirby Bauer Disc diffusion method on Muller Hinton agar. ESBL detection was done as per CLSI guidelines.

**Results:** Of the 502 isolates of *Escherichia coli*, nitrofurantoin (82%) was found to be most sensitive antimicrobial followed by amikacin (73%), gentamycin (71%) and imipenem (64%). Common empirically used antibiotics like fluoroquinolones and Cotrimoxazole drugs showed alarming rate of resistance. 60% isolates were found to be multidrug resistant. ESBL production was detected in 31% isolates. ESBL producing strains were found to be more drug resistant than non ESBL producing strains.

**Conclusions:** So, drug resistance due to production of ESBLs in *Escherichia coli* is a serious threat for clinicians. Strict infection control measures and early detection of beta lactamase producing isolates are the need of the hour to contain the emergence of this type of resistance.

**Keywords:** Antibiotic resistance, ESBL production, *Escherichia coli*, Urinary tract infection

---

**INTRODUCTION**

The urinary tract infections (UTIs) are one of the most common infectious diseases encountered in hospital as well as community settings. It is the third most common infection found in India which affects people of all age groups.¹ At some point of their lives, 10-20% women and 12% men experience an acute episode of symptomatic UTI.² UTI is much more common in women than in men, due to anatomic and physiological reasons.³ It is a serious illness in humans due to recurrence and difficulty in eradication due to emergence of drug resistance.⁴
Urinary tract infection (UTI) is caused by microbial invasion of the genitourinary tract that extends from the renal cortex of the kidney to the urethral meatus. Escherichia coli is the most common Gram negative bacteria causing both community acquired and hospital acquired UTI followed by Klebsiella spp. Proteus mirabilis, Pseudomonas aeruginosa, Acinetobacter spp. Among Gram positive bacteria, Enterococcus sp. is the most common organism responsible for UTI followed by Staphylococcus aureus and coagulase negative staphylococci especially Staphylococcus saprophyticus in sexually active females. Escherichia coli are solely responsible for more than 80% of the infections.

Emergence of antibiotic resistance in uropathogens is increasing worldwide in both outpatients as well as hospitalized patients. It varies according to geographical locales and it is directly proportional to the injudicious use of antibiotics. Emergence of antimicrobial resistance is of critical importance as the changing rate of antibiotic resistance has a large impact on the empirical therapy of urinary tract infections. Antibiotics are usually given empirically before the laboratory results of urine culture are available. To ensure appropriate therapy, current knowledge of the organisms that cause UTI and their antibiotic susceptibility is mandatory.

The various mechanisms responsible for drug resistance in Gram-negative bacilli include extended spectrum beta lactamase (ESBL) production; AmpC lactamase production, efflux mechanisms and porin deficiency. Production of beta-lactamases confer multidrug resistance, making infections difficult to treat. Clinicians often face problems in choosing appropriate antibiotic therapy for treating UTIs caused by multi-drug-resistant (MDR) bacteria.

ESBLs are plasmid mediated β-lactamases that confer resistance to broad spectrum β-lactum antibiotics including third and fourth generation cephalosporins, azetroman, and extended spectrum penicillin. These plasmids often encode mutations which confer resistance to other broad-spectrum agents including aminoglycosides, co-trimoxazole and fluoroquinolones, resulting in organism resistant to most broad spectrum antibiotics.

The detection of ESBLs is a serious challenge for routine clinical microbiology laboratories in resource limited settings which clearly leads to underreporting as well as missing of ESBL isolates resulting therapeutically failure that leads to prolonged hospital stay, increased morbidity, increased motility and high health care costs.

As urinary tract infections if not treated timely can contribute significant amount of morbidity and mortality. So, information on prevalent levels of antimicrobial resistance of a particular locale among common pathogens is useful in making an appropriate choice of empiric therapy.

This study would help clinicians to be aware of the potential of treatment failures associated with ESBL production by the organism and will also guide for appropriate empirical antimicrobial therapy as well. So that is why accurate identification of pathogens in short turnaround time and generation of authenticated results is the primary responsibility of a clinical microbiology laboratory. Keeping in view the above facts in mind, we conducted this study to determine the antimicrobial susceptibility pattern and production of ESBL strains among Escherichia coli uropathogens at study centre.

**METHODS**

A prospective study was done on all the E. coli isolates from clinically suspected cases of urinary tract infections (UTI) patients of all age groups attending OPD and IPD of tertiary care hospital of rural setting in North India. The study was of one year duration from March 2015 to February 2016. Permission was taken from Institutional Ethical committee. Mid-stream specimen of urine (MSU) was collected in sterile universal container.

Samples were transported to the laboratory without delay. Microscopical examination of urine was done by wet film preparation to detect the indicators of urinary tract infections. All samples were inoculated on Cystine Lactose Electrolyte Deficient Agar (CLED) and incubated at 37 °C for 18-24 hours, aerobically. Figure 1 showing growth of Escherichia coli on CLED agar.

![Figure 1: Growth of E. coli on CLED agar.](image)

Organisms grown in pure culture were identified by standard biochemical tests. Figure 2 Gram staining from culture of Escherichia coli depicting Gram negative bacilli.

Antibiotic susceptibility test was done by the Kirby Bauer Disc diffusion method on Muller Hinton agar. Antimicrobial agents tested were ampicillin, amoxy-clavulanic acid, gentamicin, amikacin, norfloxacin, ofloxacin, nitrofurantoin, cotrimoxazole, piperacillin-tazobactam, cefixime, cefuroxime, ceftriaxone,
ceftazidime, cefotaxime, imipenem recommended by the CLSI using *E. coli* ATCC 25922 as a standard strain for routine quality control.\(^7,8\)

**ESBL detection**

Screening and a phenotypic confirmatory test was carried out to assess the detection of ESBL, recommended by the CLSI.

**Initial screening test**

Initial screening tests recommended by the CLSI was done by Disc diffusion method by putting disc of ceftazidime, ceftriaxone and cefotaxime on Muller-Hinton agar for antibiotic sensitivity testing. Zone sizes of above antibiotics measured as per CLSI guidelines.

- Ceftazidime zone ≤22 mm
- Cefotaxime zone ≤27 mm
- Ceftriaxone zone ≤ 25 mm

Zones above may indicate ESBL production so confirmed by following test.

**Phenotypic confirmatory test**

A phenotypic confirmatory test recommended by the CLSI was done by combined disc diffusion method. ESBLs was detected by the confirmatory method of CLSI using ceftazidime (30mg) and a disc of ceftazidime plus clavulanic acid (30/10mg) were placed at a distance of 20 mm on a lawn culture (0.5 McFarland inoculum size) of suspected ESBL producing clinical isolate on Mueller-Hinton Agar (MHA, Hi-Media, Mumbai). *Escherichia coli* ATCC 25922 were used as the negative control and *Klebsiella pneumoniae* ATCC 700603 were used as the ESBL positive control.

ESBL production was inferred if the inhibition zone increased by 5mm towards the ceftazidime plus clavulanic acid disc in comparison to ceftazidime disc alone.\(^7\) Figure 3 showing ESBL production by *Escherichia coli* isolate.

![Figure 2: Gram negative bacilli of *E. coli* isolates.](image)

**Figure 3: Extended spectrum β-lactamase production by *Escherichia coli* isolate.**

**RESULTS**

A total of 3625 urine samples were received for culture and sensitivity during the study period. Among these, 798 samples (22.01 %) yielded significant bacteriuria; 2696 samples (74.3%) showed no growth and 131 samples (3.6%) showed mixed growth. The various organisms isolated from urine culture are shown in Table 1.

| Name of the organism     | Number and percentage |
|--------------------------|-----------------------|
| *Escherichia coli*       | 502 (62.9)            |
| *Klebsiella species*     | 132 (26.29)           |
| *Citrobacter species*    | 16 (2)                |
| *Pseudomonas species*    | 12 (1.50)             |
| *Proteus species*        | 4 (0.5)               |
| *Enterococcus faecalis*  | 92 (11.52)            |
| *Staphylococcus aureus*  | 25 (3.13)             |
| *Staphylococcus saprophyticus* | 4 (0.5) |
| *Candida species*        | 11 (1.38)             |
| **Total**                | 798                   |

*E. coli* was the commonest organism accounting for 62.90 per cent of the uropathogens. A total of 502 *Escherichia coli* isolates were isolated in significant numbers from patients with symptomatic UTIs. These isolates were subjected to antibiotic susceptibility testing, ESBL screening and phenotype confirmation tests.

Of the 502 *Escherichia coli* isolates, 186 were from male and 316 were from female patients. Maximum number (56%) of isolates were isolated from the age group of 15-45 years followed by (18%) each in 40-60 years and more
than 60 years of age group, 71% of patients were from rural areas whereas rest 29% belongs to urban. Higher percentages of UTI are found among the patients attending OPD (67%) as compare to IPD (33%). The antibiotic susceptibility profile of *E. coli* showed nitrofurantoin (82%) the most sensitive antimicrobial followed by amikacin (73%), gentamycin (71%) and imipenem (64%).

Among fluoroquinolones, norfloxacin showed sensitivity to only 41 % isolates while ofloxacin showed only 11% susceptibility. Sensitivity to commonly used empirical drug i.e. cotrimoxazole was merely 12%. Even imipenem showed only 64% susceptibility. Table 2 showing antibiotic susceptibility pattern of *Escherichia coli*.

**Table 2: Antibiotic susceptibility profile of *E. coli* isolates.**

| Name of antibiotics | Percentage of susceptible isolates |
|---------------------|-----------------------------------|
| Ampicillin          | 8%                                 |
| Gentamicin          | 71%                                |
| Amikacin            | 73%                                |
| Norfloxacin         | 41%                                |
| Ofloxacin           | 11%                                |
| Sulphafurazole      | 18%                                |
| Cotrimoxazole       | 12%                                |
| Nitrofurantoin      | 82%                                |
| Cefepime            | 19%                                |
| Cefixime            | 21%                                |
| Cefuroxime          | 17%                                |
| Ceftriazone         | 51%                                |
| Ceftazidime         | 23%                                |
| Imipenem            | 64%                                |
| Amoxyclav           | 7%                                 |
| Piperacillin tazobactam | 35%                              |

Of the 502 isolates, 301 (60%) isolates were found to be multidrug resistant. Of these 301 isolates, 175 (52.08%) were from OPD and 126 (76%) were from IPD. The most common risk factor associated with MDR in our study was renal pathologies like chronic renal failure, renal calculi, Diabetes mellitus of long duration and catheterization in IPD patients.

ESBL production was found in 31% of isolates. Most of ESBL producing isolates were found from IPD (58.07%) while 41.93% % were from OPD. The susceptibility pattern of *Escherichia coli* isolates-ESBL producers and ESBL non-producers to various antibiotics is being shown in the Figure 4. The most effective drug found in ESBL producers was ceftazidime clavulanic acid (100%) followed by nitrofurantoin (93.54%). Among ESBL non-producers, most susceptible antibiotic was nitrofurantoin (76.81%) followed by imipenem (71.01%). Also, multidrug resistance was common to ESBL producing strains than non ESBL producing strains.

![Figure 4: Antibiotic susceptibility profile of ESBL producing and ESBL non-producing *E. coli* isolates (%).](image_url)

**DISCUSSION**

Present study was conducted on uropathogenic *Escherichia coli* isolates as it is the most common organism isolated from community as well as hospital acquired urinary tract infections. Of the 502 isolates, 316 were isolated from female patients and maximum number i.e. 56% was in age group 15-45 years. Studies done by Ali I, Gupta V also showed predominance of *Escherichia coli* from female patients in the similar age group. This predominance in female is due to sexual activity, anatomic and physiological reasons which are directly related to increased incidence of UTI in females.

Etiology of UTI depends on various demographic characteristics that include the place of study (rural/urban). In this study, positivity rate from rural areas was 71% as compared to patients from urban areas i.e. 29%. This may be because the present study was conducted in a rural area where maximum number of patients attending the OPD/IPD was from rural background and also majority of women are least conscious about their health as well as hygienic practices.

Emergence of antimicrobial resistance is believed to be a major health problem now a day. In developing countries, scenario is even more worrisome because of availability of antibiotics over the counter. As Cotrimoxazole is considered as first line empirical treatment for many years, increasing frequency of resistance to cotrimoxazole is troublesome. In this study too only 12 % sensitivity
was observed to cotrimoxazole. According to the literature fluoroquinolones are acclaimed as initial empirical therapy for uncomplicated UTI in areas where resistance to cotrimoxazole exceeds 20%. In this study, *Escherichia coli* showed alarming reduced susceptibilities to fluoroquinolones like norfloxacin and Ofloxacin. Studies done by Mandel J et al and Ali I et al, showed same alarming results for fluoroquinolones. This is a warning call for judicious use of fluoroquinolones. Cephalosporins commonly prescribed drugs, even on an outpatient basis showed same scenario as fluoroquinolones. This results were consistent with study done by Farshad S. Resistance shown by combination of drugs like amoxicillin-clavulanic acid; piperacillin-tazobactam was even more worrying. Studies done by Hena Rani et al and Varsha Gupta et al showed 83.6% and 90.6% resistance to amoxy clavulanic acid which is in concordance with this study. While both the above studies showed 1.9% and 6.6% resistance to piperacillin tazobactam which is very much less as compared to our study 35%, reason for this high resistance in this study could be more use of this drug in our set up. In this study, highest sensitivity was shown by nitrofurantoin (82%) followed by amikacin (73%), gentamycin (71%). Higher percentage of susceptibilities to the above drugs shown by Hena Rani et al and Varsha Gupta et al was in concordance with this study.

Rate of ESBL production by *Escherichia coli* in our study was 31%. ESBLs production cause therapeutic failure with cephalosporins and aztreonam when host organism appears to be susceptible to these agents in laboratory tests. Hence, CLSI recommends that laboratories should report ESBL producing isolates as resistant to all penicillins, cephalosporins (including cefepime and cefpirome), and aztreonam irrespective of *in-vitro* test results.

ESBL producing *Escherichia coli* varies greatly among country and among the hospitals within the country. This Variation is because of range of factors including species, geographic locality, hospital/ward, group of patients and type of infection, and large variations have been reported in different studies. Studies done by Tankhiwala SS et al showed lower percentage of ESBL isolates i.e. 18.5%. Higher percentage of ESBL producing *Escherichia coli* was found by Neelam Taneja et al with a rate of 40.2 % while Gupta V showed 52.6%. Present study showed higher percentage of resistance in ESBL producing *E. coli* as compared to ESBL non-producers. Multidrug resistance in *Escherichia coli* were seen in most of the strains and majority of them were ESBL producer.

As indicated by the present findings together with previous findings, it appears to be mandatory to include ESBL detection in routine laboratory practice so as to limit the rapid spread of ESBL-producing organisms.

**CONCLUSION**

So, drug resistance due to ESBL production is a serious threat in UTI narrowing down the choice of antibiotics for treatment. So, there is dire need to introduce routine screening for ESBL production for all uropathogenic *Escherichia coli* causing urinary tract infection. Early detection of beta lactamase will avoid treatment failure, as often the isolates producing these enzymes show a susceptible phenotype in routine susceptibility test.

**Funding:** No funding sources

**Conflict of interest:** None declared

**Ethical approval:** The study was approved by the Institutional Ethics Committee

**REFERENCES**

1. Chaturvedi A, Garg R, Singh VA. Comparative evaluation of different culture media for the isolation and identification of common urinary pathogens. Int J Res Med Sci. 2017;5(8):3676-9.
2. Shariff VA AR, Shenoy MS, Yadav T, Radhakrishna M. The antibiotic susceptibility pattern of uropathogenic *Escherichia coli*, with special reference to the fluoroquinolones. J Clin Diag Res. 2013;7(6):1027-30.
3. Shakya P, Shrestha D, Maharjan E, Sharma VK, Paudyal R. ESBL production among *E. coli* and Klebsiella spp. Causing Urinary Tract Infections: A Hospital Based Study. The Open Microbiology J. 2017;11:23-30.
4. Arjunan M, AL-Salamah AA, Amuthan M. Prevalence and antibiotics susceptibility of uropathogens in patients from a rural environment, Tamilnadu. Ann J Infect Dis. 2010;6(2):29-33.
5. Kibert M, Abera B. Prevelence and Antibiogram of bacterial isolates from urinary tract infections at Dessie Health Research Laboratory, Ethiopia. Asian Pac J Trop Biomed. 2014;4(2):164-8.
6. Higashide M, Kuroda M, Omura CTN, Kumano M, Ohkawa S, Ichimura S et al. Meticillin resistant Staphylococcus saprophyticus isolates carrying Staphylococcal Cassette Chromosome mec Have emerged in Urogenital Tract Infections. Antimicrobial Agents Chemotherapy. 2008;52(6):2061-8.
7. Gupta K, Sahm DF, Mayfield D, Stamm WE. Antimicrobial resistance among uropathogens that cause community acquired urinary tract infections in women: A nationwide analysis. Clin Infect Dis. 2001;33:89-94.
8. Varsha Gupta, Aparna Yadav, RM Joshi. Antibiotic resistance pattern in uropathogens. Indian J Medical Microbiol. 2002;20:96-8.
9. Taneja N, Rao P, Arora J, Dogra A. Occurrence of ESBL and Amp-C β-lactamases and susceptibility to newer antimicrobial agents in complicated UTI. Indian J Med Res. 2008;127:85-8.
10. Black IA, Moland ES, Thomson KS. AmpC disk test for detection of plasmid-mediated AmpC- b lactamases in Enterobacteriaceae lacking chromosomal AmpC- blactamases. J Clin Microbiol. 2005;43:3110-3.

11. Banerjee S, Sengupta M, Sarker TK. Fosfomycin susceptibility among multidrug resistant, extended spectrum beta- lactamase producing, carbapenem-resistant Uropathogens. Indian J Urol. 2017;33(2):149-54.

12. National Centre for Disease Control. National treatment guidelines for antimicrobial use in infectious disease. Version 1.0: 2016:42. Available at:http://pbhealth.gov.in/AMR_guideline7001495889.pdf.

13. Halwarkar AK, Sataraddi J, Gupta S, Yoganand R, Rao A, Srinivasa H. The detection of ESBL-producing Escherichia coli in patients with symptomatic urinary tract infections using different diffusion methods in a rural setting. J Infection Pub Heal. 2013;6:108-14.

14. Mehrgan H, Rahbar M. Prevalence of extended-spectrum beta-lactamase-producing Escherichia coli in a tertiary care hospital in Tehran, Iran. Int J Antimicrob Agents. 2008;31(2):147-51.

15. Ko KS, Suh JY, Peck KR, Lee MY, Oh WS, Kwon KT, et al. In vitro activity of fosfomycin against ciprofloxacin-resistant or extended-spectrum β- lactamase-producing Escherichia coli isolated from urine and blood. Diag Microbiol Infec Dis. 2007;58(1):111-5.

16. Collee JG, Miles RS, Watt B. Tests for the identification of bacteria. In: Collee JG, Fraser AG, Marmion BP, Simmons A, eds. Mackie and MacCartney practical medical microbiology, 14th ed. Edinburgh: Churchill Livingstone;1996:151-79.

17. Bauer AW, Kirby WMM, Sherris JC, Turck M. Antibiotic susceptibility testing by a standardized single disc method. Am J Clin Pathol. 1966;45:493-6.

18. CLSI. Performance standards for antimicrobial susceptibility testing; 23rd Informational Supplement. CLSI Document M100-S23, Wayne PA: Clinical and Laboratory Standards Institute;2013.

19. Ali I, Shabhir M, UI Iman N. Antibiotics susceptibility pattern of uropathogenic E. coli with special reference to fluoroquinolones in different age and gender groups. J Pak Med Assoc. 2017;67(8):1161-5.

20. Mandal J, Acharya NS, Buddhapriya D, Parija SC. Antibiotic resistance pattern among common bacterial uropathogens with a special reference to ciprofloxacin resistant Escherichia coli. Indian J Med Res. 2012;136:842-9.

21. Farshad S, Ranjar B, Anvarinejad M, Shahidi M A, Hosseini M. Emergence of multi drug resistant strains of Escherichia coli isolated from urinary tract infection. The Open Conference Proceedings J. 2010;1:192-6.

22. Rani H, Kaistha N, Gupta V, Chander J. Choice of Antibiotics in Community Acquired UTI due to Escherichia Coli in the Adult Age group. J Clin Diag Res. 2011;5(3):483-5.

23. Gupta V, Rani H, Singla N, Kaistha N, Chander J. Determination of extended-spectrum b-lactamases and AmpC production in uropathogenic isolates of Escherichia coli and susceptibility to fosfomycin. J Laboratory Physicians. 2013;5(2):90-3.

24. Livermore DM, Canton R, Gniadkowski M, Nordmann P, Rossolini GM, Arlet G, et al. CTX-M: changing the face of ESBLs in Europe. J Antimicro Chemothery. 2007 Feb 1;59(2):165-74.

25. Tankhiwale SS, Jalgaonkar SV, Ahmed S, Hassani U. Evaluation of extended spectrum beta lactamase in urinary isolates. Ind J Med Res. 2004;120:553-6.

Cite this article as: Rahman MS, Garg R, Singh VA, Biswas D. Antibiotic susceptibility profile and extended spectrum β-lactamases production by uropathogenic Escherichia coli from tertiary care hospital of rural settings. Int J Res Med Sci 2018;6:4022-7.